249 related articles for article (PubMed ID: 18044080)
1. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.
Zaulyanov L; Kirsner RS
Clin Interv Aging; 2007; 2(1):93-8. PubMed ID: 18044080
[TBL] [Abstract][Full Text] [Related]
2. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
Curran MP; Plosker GL
BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
[TBL] [Abstract][Full Text] [Related]
3. Apligraf--a living human skin equivalent for the treatment of chronic wounds.
Streit M; Braathen LR
Int J Artif Organs; 2000 Dec; 23(12):831-3. PubMed ID: 11197742
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
Langer A; Rogowski W
BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
[TBL] [Abstract][Full Text] [Related]
5. Innovative therapies in wound healing.
Shen JT; Falanga V
J Cutan Med Surg; 2003; 7(3):217-24. PubMed ID: 12704530
[TBL] [Abstract][Full Text] [Related]
6. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
Trent JF; Kirsner RS
Int J Clin Pract; 1998 Sep; 52(6):408-13. PubMed ID: 9894378
[TBL] [Abstract][Full Text] [Related]
7. Utilization of living bilayered cell therapy (Apligraf) for heel ulcers.
Karr J
Adv Skin Wound Care; 2008 Jun; 21(6):270-4. PubMed ID: 18525250
[TBL] [Abstract][Full Text] [Related]
8. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers.
Steinberg JS; Edmonds M; Hurley DP; King WN
J Am Podiatr Med Assoc; 2010; 100(1):73-7. PubMed ID: 20093548
[TBL] [Abstract][Full Text] [Related]
9. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
Zelen CM; Gould L; Serena TE; Carter MJ; Keller J; Li WW
Int Wound J; 2015 Dec; 12(6):724-32. PubMed ID: 25424146
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
Zelen CM; Serena TE; Gould L; Le L; Carter MJ; Keller J; Li WW
Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf).
Karr JC
Adv Skin Wound Care; 2011 Mar; 24(3):119-25. PubMed ID: 21326023
[TBL] [Abstract][Full Text] [Related]
13. The use of Apligraf in acute wounds.
Kirsner RS
J Dermatol; 1998 Dec; 25(12):805-11. PubMed ID: 9990773
[TBL] [Abstract][Full Text] [Related]
14. Apligraf in the treatment of neuropathic diabetic foot ulcers.
Edmonds M;
Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers.
Fivenson D; Scherschun L
Int J Dermatol; 2003 Dec; 42(12):960-5. PubMed ID: 14636194
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
Redekop WK; McDonnell J; Verboom P; Lovas K; Kalo Z
Pharmacoeconomics; 2003; 21(16):1171-83. PubMed ID: 14594438
[TBL] [Abstract][Full Text] [Related]
17. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success.
Saco M; Howe N; Nathoo R; Cherpelis B
Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617934
[TBL] [Abstract][Full Text] [Related]
18. The role of Apligraf in the treatment of venous leg ulcers.
Dolynchuk K; Hull P; Guenther L; Sibbald RG; Brassard A; Cooling M; Delorme L; Gulliver W; Bourassa DH; Ho V; Kunimoto B; Overholt T; Papp K; Tousignant J
Ostomy Wound Manage; 1999 Jan; 45(1):34-43. PubMed ID: 10085970
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of Apligraf in the treatment of diabetic foot ulcers.
Dinh TL; Veves A
Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):152S-157S; discussion 158S-159S. PubMed ID: 16799383
[TBL] [Abstract][Full Text] [Related]
20. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes.
Barber C; Watt A; Pham C; Humphreys K; Penington A; Mutimer K; Edwards M; Maddern G
J Wound Care; 2008 Dec; 17(12):517-27. PubMed ID: 19052516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
